BGAI
KPTI icon

Bruce G. Allen Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Bruce G. Allen Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22
Closed -$144 – 1108
2025
Q3 		$144 Hold
22
– – ﹤0.01% 1071
2025
Q2 		$95 Hold
22
– – ﹤0.01% 1074
2025
Q1 		$82 Sell
22
-1
-4% -$9 ﹤0.01% 1083
2024
Q4 		$229 Hold
23
– – ﹤0.01% 1054
2024
Q3 		$281 Sell
23
-11
-32% -$137 ﹤0.01% 1058
2024
Q2 		$440 Hold
34
– – ﹤0.01% 872
2024
Q1 		$766 Hold
34
– – ﹤0.01% 814
2023
Q4 		$439 Buy
+34
New +$458 ﹤0.01% 919

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Bruce G. Allen Investments's KPTI Position: Q4 2025 in Review

Bruce G. Allen Investments sold out of Karyopharm Therapeutics (KPTI) in Q4 2025, closing a stake of 22 shares — an estimated $144 sold.

Bruce G. Allen Investments first reported a position in KPTI in Q4 2023 and held it in 8 quarters. The position peaked at $766 in Q1 2024. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • Bruce G. Allen Investments reported no remaining Karyopharm Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bruce G. Allen Investments sold 22 Karyopharm Therapeutics shares in Q4 2025, an estimated $144.
  • Bruce G. Allen Investments first reported a position in Karyopharm Therapeutics in Q4 2023 and held it in 8 quarters.
  • Bruce G. Allen Investments's Karyopharm Therapeutics position peaked at $766 in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on Bruce G. Allen Investments's 13F filing for Q4 2025, filed 10 Feb 2026.